Related Experiment Video
Updated: Aug 16, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MUC1 as a target antigen for cancer immunotherapy
Bruce Acres1, Jean-Marc Limacher
1Department of Medical and Regulatory Affairs, Transgene, 67082 Strasbourg, France. acres@transgene.fr
Abstract:
The cancer-associated antigen MUC1 is overexpressed and modified by tumor cells in over half of all cancer cases. Despite various complexities associated with this antigen, it is well worth pursuing as a vaccine for the immunotherapy of cancer. In this review, the authors describe the discovery of MUC1 and its association with cancer, recent observations showing that the immunology of MUC1 is complicated, animal data showing that it can be a target for immune-mediated tumor rejection, and finally, preliminary clinical results to show that vaccine-based immunotherapy with MUC1 does have an impact on the therapy of cancer.
Related Concept Videos
Mitogens and the Cell Cycle
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Abnormal Proliferation
